Advances in pharmacotherapy for wet age-related macular degeneration

Bibliography

• Nita M, Strzałka-mrozik B, Grzybowski A, et al. Age-related macular degeneration and changes in the extracellular matrix. Med Sci Monit 2014;20:1003-16
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica 2012;227(Suppl 1):11-20
   PubMed Web of Science ®Google Scholar
• Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med 2012;33:295-317
   PubMed Web of Science ®Google Scholar
• Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008;68:1029-36
   PubMed Web of Science ®Google Scholar
• La Cour M, Kiilgaard JF, Nissen MH. Age-related macular degeneration: epidemiology and optimal treatment. Drugs Aging 2002;19:101-33
   PubMed Web of Science ®Google Scholar
• Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron 2012;75:26-39
   PubMed Web of Science ®Google Scholar
• Mcleod DS, Taomoto M, Otsuji T, et al. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2002;43:1986-93
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000;4:1983-91
   Google Scholar
• Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 2012;49:24-40
   PubMed Web of Science ®Google Scholar
• Gass JD. Photocoagulation of macular lesions. Trans Am Acad Ophthalmol Otolaryngol 1971;75:580-608
   PubMedGoogle Scholar
• Campa C, Costagliola C, Incorvaia C, et al. Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm 2010
   PubMed Web of Science ®Google Scholar
• De oliveira dias JR, Rodrigues EB, Maia M, et al. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 2011;95:1631-7
   PubMed Web of Science ®Google Scholar
• Gaengel K, Genové G, Armulik A, et al. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009;29:630-8
   PubMed Web of Science ®Google Scholar
• Miao H, Tao Y, Li XX. Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization. Mol Vis 2012;18:574-80
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Lanzetta P. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors. J Ocul Pharmacol Ther 2013;29:437-41
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-21
   PubMed Web of Science ®Google Scholar
• Moutray T, Chakravarthy U. Age-related macular degeneration: current treatment and future options. Ther Adv Chronic Dis 2011;2:325-31
   PubMedGoogle Scholar
• Ramasamy K. Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007;55:413-15
   PubMedGoogle Scholar
• Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. Available from: http://www.nice.org.uk/guidance/ta155
   Google Scholar
• Macugen® (pegaptanib sodium injection). Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf
   Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ETJr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014;98:1144-67
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Adamis AP, Cunningham ETJr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508e1-25
   Google Scholar
• Lucentis® (ranibizumab injection). Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf
   Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-83
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9
   PubMed Web of Science ®Google Scholar
• Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmology 2008;145:239-48
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9
   PubMed Web of Science ®Google Scholar
• Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmology 2007;143:566-83
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98
   PubMed Web of Science ®Google Scholar
• Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013;120:130-9
   PubMed Web of Science ®Google Scholar
• Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56
   PubMed Web of Science ®Google Scholar
• Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmology 2010;94:2-13
   PubMed Web of Science ®Google Scholar
• Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS). Available from: www.clinicaltrials.gov/ct2/show/NCT01318941?term=NCT01318941&rank=1
   Google Scholar
• Avastin® (bevacizumab). Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s301lbl.pdf
   Google Scholar
• Schmucker C, Ehlken C, Agostini HT, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 2012;7(8):e42701
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411
   PubMed Web of Science ®Google Scholar
• Eylea® (aflibercept Injection). Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/125387s043lbl.pdf
   Google Scholar
• Semeraro F, Morescalchi F, Duse S, et al. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther 2013;7:711-22
   PubMed Web of Science ®Google Scholar
• Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-93
   PubMed Web of Science ®Google Scholar
• Selvaraj SK, Giri RK, Perelman N, et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003;102:1515-24
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83
   PubMed Web of Science ®Google Scholar
• Castellon R, Hamdi HK, Sacerio I, et al. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 2002;74:523-35
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201
   PubMed Web of Science ®Google Scholar
• A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration. Available from: www.clinicaltrials.gov/ct2/show/NCT00569140?term=e10030+amd&rank=5
   Google Scholar
• Kaiser PK. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline. Ophthalmology 2013;120:(Suppl 5):11-5
   Web of Science ®Google Scholar
• Kaiser RS. Anti-PDGF Combination Therapy for AMD. Results of a phase 2 study. Retina Today 2013. Available from: www.retinatoday.com/pdfs/0513RT_F3_Kaiser.pdf
   Google Scholar
• Fovista Phase 2b Data Show Reduction in Subretinal Fibrosis Using Fovista Combination Therapy vs Anti-VEGF Monotherapy. Available from: www.asrs.org/education/clinical-updates/350/fovista-phase-2b-data-show-reduction-in-subretinal-fibrosis-using-fovista-combination-therapy-vs-antivegf-monotherapy
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Annual report on form 10-K. Available from: http://investor.regeneron.com/secfiling.cfm?filingID=1532176-14-8&CIK=872589
   Google Scholar
• Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD. Available from: www.clinicaltrials.gov/ct2/show/NCT02061865?term=REGN2176-3&rank=1
   Google Scholar
• Wang F, Bai Y, Yu W, et al. Anti-angiogenic effect of KH902 on retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 2013;251:2131-9
   PubMed Web of Science ®Google Scholar
• Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 2014;121:1740-7
   PubMed Web of Science ®Google Scholar
• Zhou AY, Bai YJ, Zhao M, et al. KH902, a recombinant human VEGF receptor fusion protein, reduced the level of placental growth factor in alkali burn induced-corneal neovascularization. Ophthalmic Res 2013;50:180-6
   PubMed Web of Science ®Google Scholar
• Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009;26:204-10
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis 2008;14:37-49
   PubMed Web of Science ®Google Scholar
• Li H, Lei N, Zhang M, et al. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 2012;97:154-9
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011;118:672-8
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Dugel PU. Reaching New Heights. Retina 2014. Available from: www.aao.org/pdf/AAOSub2014_RET_syllabus.pdf
   Google Scholar
• Conbercept Requires Lower Dosing Frequency, Provides Visual Acuity Improvements Equal to Other Anti-VEGF Agents. Available from: www.retinatoday.com/2014/03/14/conbercept-requires-lower-dosing-frequency-provides-visual-acuity-improvements-equal-to-other-anti-vegf-agents
   Google Scholar
• A randomized, double-masked, multicenter, sham-controlled, safety and efficacy study of KH902 in patients with wet AMD (PHOENIX). Available from: www.clinicaltrials.gov/ct2/show/NCT01436864
   Google Scholar
• Lanzetta P, Weichselberger A, Weissgerber G. Randomized controlled trial assessing safety and preliminary efficacy Of Rth258 (ESBA1008), a novel single-chain Fv antibody fragment, in neovascular age-related macular degeneration. Proceeding of The 6th World Congress on Controversies in Ophthalmology (COPHy); 26-29 March 2015; Sorrento, Italy
   Google Scholar
• Dugel P. Results of ESBA 1008, a single-chain antibody fragment for the treatment of neovascular AMD. Proceeding of American Society of Retina Specialists Annual Meeting; 9-13 August 2014; San Diego, CA
   Google Scholar
• Efficacy and Safety Study of ESBA1008 Versus EYLEA®. Available from: www.clinicaltrials.gov/ct2/show/NCT01796964?term=NCT01796964&rank=1
   Google Scholar
• Efficacy and Safety of RTH258 Versus Aflibercept. Available from: www.clinicaltrials.gov/ct2/show/NCT02307682?term=NCT02307682&rank=1
   Google Scholar
• Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2008;2:377-88
   PubMedGoogle Scholar
• Sills AKJr, Williams JI, Tyler BM, et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998;58:2784-92
   PubMed Web of Science ®Google Scholar
• Genaidy M, Kazi AA, Peyman GA, et al. Effect of squalamine on iris neovascularization in monkeys. Retina 2002;22:772-8
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007;23:477-87
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD). Available from: www.clinicaltrials.gov/ct2/show/NCT01678963
   Google Scholar
• Squalamine. Ohr Pharmaceutical Inc. Available from: www.ohrpharmaceutical.com/research/squalamine
   Google Scholar
• Singer M. Advances in the management of macular degeneration. F1000Prime Rep 2014;6:29
   PubMedGoogle Scholar
• PAN-90806: Our lead development compound. PanOptica. Available from: www.panopticapharma.com/pan.html
   Google Scholar
• Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD. Available from: www.clinicaltrials.gov/ct2/show/NCT02022540
   Google Scholar
• Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov Today 2008;13:695-701
   PubMed Web of Science ®Google Scholar
• Boersma YL, Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol 2011;22:849-57
   PubMed Web of Science ®Google Scholar
• Binz HK, Amstutz P, Kohl A, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004;22:575-82
   PubMed Web of Science ®Google Scholar
• Abicipar. Molecular partners. Available from: www.molecularpartners.com/our-products/abiciparandmulti-vegf_pdgf
   Google Scholar
• Phase 2 Study for DARPin abicipar pegol in wet AMD. Molecular Partners. Available from: www.molecularpartners.com/positive-top-line-data-reported-from-phase-2-study-for-darpin-abicipar-pegol-in-wet-amd/
   Google Scholar
• Stage 3 Phase 2 study of DARPin abicipar pegol (previously MP0112) supports progressing to phase III development program. Business wire 2014. Available from: www.businesswire.com/news/home/20140701005546/en/Stage-3-Phase-2-study-DARPin-abicipar
   Google Scholar
• Barik S. Development of gene-specific double-stranded RNA drugs. Ann Med 2004;36:540-51
   PubMed Web of Science ®Google Scholar
• Hanout M, Ferraz D, Ansari M, et al. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed Res Int 2013;2013:830837
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Schachar RA, Nduaka CI, et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 2012;53:7666-74
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Inoki K, Guan KL. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 2005;280:9769-72
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Schachar RA, Nduaka CI, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology 2012;119:1867-73
   PubMed Web of Science ®Google Scholar
• Pilot Study of X-82 in Patients With Wet AMD. Available from: www.clinicaltrials.gov/ct2/show/NCT01674569?term=X82&rank=3
   Google Scholar
• ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Physiology/Pharmacology. Available from: www.arvo.org/webs/am2013/abstract/section/physiology_pharmacology.pdf
   Google Scholar
• Votrient® (pazopanib tablets). Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf
   Google Scholar
• Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 2008;17:253-61
   PubMed Web of Science ®Google Scholar
• Csaky KG, Dugel PU, Pierce AJ, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology 2015;122:579-88
   PubMed Web of Science ®Google Scholar
• ZimuraTM Ophthotech. Available from: www.ophthotech.com/product-candidates/arc1905
   Google Scholar
• ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration. Available from: www.clinicaltrials.gov/ct2/show/study/NCT00709527?term=ARC+1905&rank=2
   Google Scholar
• A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration. Available from: www.clinicaltrials.gov/ct2/show/NCT00950638?term=arc+1905&rank=1
   Google Scholar
• Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012;11:541-59
   PubMed Web of Science ®Google Scholar
• Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP). Available from: www.clinicaltrials.gov/ct2/show/NCT00473928?term=POT-4&rank=1
   Google Scholar
• Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (RACE). Available from: www.clinicaltrials.gov/ct2/show/results/NCT01157065?term=AL-78898A++amd+ranibizumab&rank=1&sect=X870156#outcome2
   Google Scholar
• Sabbadini RA. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol 2011;162:1225-38
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (Nexus). Available from: www.clinicaltrials.gov/ct2/show/NCT01414153?term=isonep&rank=2
   Google Scholar
• Volociximab: α5β1 Antagonist - Wet AMD Intravitreal. Available from: www.amdbook.org/content/volociximab-%CE%B15%CE%B21-antagonist-wet-amd-intravitreal
   Google Scholar
• A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration. Available from: www.clinicaltrials.gov/ct2/show/record/NCT00782093?term=volociximab
   Google Scholar
• Krader CG. Novel combination regimen for AMD shows favorable safety. Early data yield promising results for volociximab/anti-VEGF therapy for neovascular AMD. Ophthalmology Times 2010. Available from: http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/clinical/clinical-pharmacology/novel-combination-regimen-amd-shows-favorable?id=&sk=&date=&%0A%09%09%09=&pageID=2
   Google Scholar
• Quiroz-Mercado H. Integrin peptide therapy in choroidal and retinal neovascularisation. Retina Today 2013. Available from: http://retinatoday.com/2013/09/integrin-peptide-therapy-in-choroidal-and-retinal-neovascularization/
   Google Scholar
• A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01749891
   Google Scholar
• Nelson R. Integrin peptide for AMD emerging. Ophthalmology Times 2013. Available from: http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/content/tags/alg-1001/integrin-peptide-amd-emerging?page=full
   Google Scholar
• Ishikawa M, Jin D, Sawada Y, et al. Future therapies of wet age-related macular degeneration. J Ophthalmol 2015.2015:138070 Available from: http://www.hindawi.com/journals/joph/2015/138070/#B53
   Google Scholar
• Rubio RG. Long-Acting Anti-VEGF Delivery. The potential of a posterior segment delivery system was evaluated in a phase 1 trial. Retina today 2014. Available from: retinatoday.com/2014/08/long-acting-anti-vegf-delivery
   Google Scholar
• Replenish, Inc. Product Description and Device Development. Available from: http://replenishinc.com/our-technology/product-description
   Google Scholar
• Gutiérrez-Hernández J-C, Caffey S, Abdallah W, et al. One-year feasibility study of replenish micropump for intravitreal drug delivery: A pilot study. Transl Vis Sci Technol 2014;3:8
   PubMed Web of Science ®Google Scholar
• Humayun M, Santos A, Altamirano JC, et al. Implantable micropump for drug delivery in patients with diabetic macular edema. Transl Vis Sci Technol 2014;3:5
   PubMed Web of Science ®Google Scholar
• NT-503 ECT. Available from: www.neurotechusa.com/VEGF-Antagonist.html
   Google Scholar
• AMD Update 14: Neurotech Pharmaceuticals NT-501 Implant Shown to Slow Vision Loss in Patients with Geographical Atrophy Associated with Dry AMD. Available from: www.irvaronsjournal.blogspot.it/2011/04/amd-update-14-neurotech-pharmaceuticals.html
   Google Scholar
• Kauper K, Rivera M, Mills J, et al. Design considerations and performance of a next-generation encapsulated cell technology intraocular implant delivering VEGF-antagonist. ARVO 2014; Annual Meeting Abstracts
   Google Scholar
• Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). Available from: www.clinicaltrials.gov/ct2/show/NCT02228304?term=NT+503&rank=1
   Google Scholar
• MacLachlan TK, Lukason M, Collins M, et al. Preclinical safety evaluation ofAAV2-sFLT01 a gene therapy for age-related macular degeneration. Mol Ther 2011;19:326-34
   PubMed Web of Science ®Google Scholar
• Lukason M, Dufresne E, Rubin H, et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 2011;19:260-5
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-76
   PubMed Web of Science ®Google Scholar
• Lanzetta P, Mitchell P, Wolf S, et al. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. Br J Ophthalmol 2013;97:1497-507
   PubMed Web of Science ®Google Scholar
• Gabai A, Veritti D, Lanzetta P. One-year outcome of ranibizumab for neovascular age-related acular degeneration: a thorough analysis in a real-world clinical setting. Eur J Ophthalmol 2014;24:396-401
   PubMed Web of Science ®Google Scholar
• Veritti D, Macor S, Menchini F, et al. Effects of VEGF inhibition on retinal morphology, neovascular network size, and visual acuity in patients with vascularized pigment epithelium detachment because of occult choroidal neovascularization. Retina 2013;33:982-9
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121:150-61
   PubMed Web of Science ®Google Scholar
• Horie-Inoue K, Inoue S. Genomic aspects of age-related macular degeneration. Biochem Biophys Res Commun 2014;452:263-75
   PubMed Web of Science ®Google Scholar
• Chowers I, Meir T, Lederman M, et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol Vis 2008;14:2263-71
   PubMed Web of Science ®Google Scholar
• Ross RJ, Verma V, Rosenberg KI, et al. Genetic markers and biomarkers for age-related macular degeneration. Expert Rev Ophthalmol 2007;2:443-57
   PubMedGoogle Scholar